

Moderna and Pfizer/BioNTech COVID-19 vaccines, bivalent authorized down to 6 months old – CDC approves

- On December 8, 2022, the [Centers for Disease Control and Prevention \(CDC\) expanded](#) the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years.
 - The approval quickly followed the [FDA's action](#) for the Moderna and Pfizer/BioNTech bivalent vaccines.
 - All individuals seeking a Moderna COVID-19 booster who are ages 6 months and older should receive the Moderna bivalent vaccine.
 - Individuals 6 months to 4 years of age seeking a third dose of the Pfizer/BioNTech vaccination series should receive the Pfizer/BioNTech bivalent vaccine instead of the monovalent third dose.
- Only about [1.6 million individuals <5 years of age](#) have received at least one dose of vaccine since June 18, 2022. This means that about 95% of children <5 years of age are not vaccinated or have only received one dose.
- The U.S. government has already purchased bivalent booster doses for children. The Pfizer/BioNTech and Moderna bivalent vaccine vials for children have been available for [pre-ordering](#).
- With the CDC's recommendation, pharmacies and other administration sites may begin administering bivalent booster vaccine to appropriate children when they have supply.
- Updated information about Moderna and Pfizer/BioNTech's bivalent vaccines for children 6 months to 5 years of age will be posted on the [CDC website](#).